A recent op-ed by Joseph Stiglitz wrongly paints efforts to protect medical intellectual property (IP) as a grand conspiracy by drug companies. In fact, IP rights are a central tool for protecting the global innovation ecosystem and insuring that next generation medications and treatments make it to market.
